Isomorphic Labs partners with MSD to apply AI-driven drug design to oncology, with upfront payment and milestone royalties
The collaboration, announced on 19 November 2026, joins Isomorphic Labs' in‑silico platform with MSD's curated data sets. It aims to generate small‑molecule candidates for a strategically important cancer indication while assigning development and commercialization to MSD.
Isomorphic Labs and MSD announced their research collaboration on Nov. 19, 2026.1
In November 2026, Isomorphic Labs announced a Series C financing led by Greenoaks and Sequoia Capital.4
Isomorphic Labs’ stated goal is to move its first treatment programs into clinical trials by the end of 2026, after an earlier end-of-2025 goal.3
Story
Isomorphic Labs partners with MSD to apply AI-driven drug design to oncology, with upfront payment and milestone royaltiesOn 19 November 2026 Isomorphic Labs and MSD disclosed a research partnership focused on oncology drug discovery.1 The two firms intend to generate small‑molecule therapeutic candidates for an oncology indication they label as strategically important.1 Isomorphic Labs will contribute computational predictions and molecular designs through its IsoDDE engine.1 MSD will supply proprietary, high‑quality curated datasets to support the joint effort.1 Together, these contributions connect computational design with curated research information, while the intended output remains potential candidates rather than established medicines.1
Under the agreement MSD will assume responsibility for pre‑clinical and clinical development, manufacturing, and eventual commercialization of any products emerging from the collaboration.1 Isomorphic Labs is slated to receive an upfront payment and may earn additional sums linked to research, development, regulatory, and commercial milestones, together with tiered net‑sales royalties.1 The company also retains the option to co‑fund development activities in exchange for higher royalty rates.1 These financial terms tie Isomorphic Labs' compensation to the progress and success of the joint programme.1 The arrangement therefore gives Isomorphic Labs a choice: it can receive milestone-linked payments and royalties, or elect to share development costs in return for higher royalties.1 MSD's responsibilities extend beyond research support to development and the eventual production and sale of any resulting products.1
Research director Sarah Skerratt explained that the partnership will leverage the firm’s drug‑design platform to advance discovery work.1 She emphasized that the AI‑driven approach is intended to accelerate the identification of viable candidates.1 MSD Research Laboratories executive George Addona highlighted the importance of close coordination between wet‑lab and dry‑lab activities for effective AI‑enabled molecular invention.1 Addona’s comment underscores the collaborative workflow envisioned by the agreement.1 The remarks point to complementary contributions: Isomorphic Labs provides computational design, while MSD supplies datasets and leads later development work.1 That division makes coordination relevant across the partnership, linking Isomorphic Labs' design work with MSD's research resources and responsibilities.1
Isomorphic Labs, founded in 2021, operates from London with additional sites in Cambridge, Massachusetts, and Lausanne, Switzerland.1 The new partnership follows earlier collaborations with Eli Lilly and Novartis that were announced in January 2024.2 Those prior deals illustrate a pattern of Isomorphic Labs partnering with large pharmaceutical firms to apply its AI capabilities.2 The current arrangement is described as a blend of Isomorphic Labs’ AI drug‑discovery approach with MSD’s proprietary data resources and discovery experience.1 The earlier agreements provide context for the MSD deal: Isomorphic Labs had announced partnerships with Eli Lilly and Novartis before this collaboration.12 Its London base and offices in Cambridge and Lausanne show the locations the company lists alongside its partnership activity.12
In the same month the company secured a $5 billion Series C financing round led by Greenoaks and Sequoia Capital.4 This financing builds on a $2.1 billion Series B that was announced in May of the same year.4 The capital influx is intended to support the expansion of Isomorphic Labs’ AI platform and its growing pipeline of candidates.4 These large funding rounds reflect investor confidence in the company’s AI‑driven model.4 The reported Series C financing exceeded the Series B amount, making the later announced round the larger of the two reported financings.4 The figures show the scale of the company's reported financing, alongside its stated effort to develop treatment programs and partnerships.234
The collaboration’s focus is on discovery‑stage oncology candidates rather than on molecules already in clinical testing.1 Consequently, the early work will generate novel molecular designs that must later undergo pre‑clinical and clinical evaluation.1 Clinical development carries a substantial risk of failure, as drug candidates must still be proven safe and effective in people.3 This risk profile underscores the importance of MSD’s role in later‑stage development and commercialization.1 For people awaiting treatments, the distinction is important: the agreement concerns candidate discovery, not products already shown to be safe and effective in people.13 Any candidates that emerge would still face preclinical and clinical development, and the facts describe clinical work as carrying substantial failure risk.13
Isomorphic Labs has set a goal to advance its first treatment programmes into clinical trials by the end of 2026.3 That target was previously aimed at the end of 2025 but has been pushed back.3 The delay reflects the challenges inherent in moving AI‑generated candidates through the validation pipeline.3 Achieving the revised timeline will depend on the efficiency of the partnership’s discovery and hand‑off processes.1 The stated target is now one year later than the earlier end-of-2025 goal, so the first-trial ambition has shifted rather than been achieved already.3 The timeline matters because the candidates still need testing in people for safety and effectiveness, with clinical development carrying substantial risk.3
The partnership illustrates a broader industry trend of integrating artificial intelligence with traditional pharmaceutical expertise.1 By combining Isomorphic Labs’ computational design capabilities with MSD’s data assets and development infrastructure, the collaboration seeks to shorten the path from concept to clinic.1 If successful, the model could serve as a template for future AI‑driven drug discovery alliances.1 The outcome will be measured by the number of viable oncology candidates that progress to pre‑clinical testing and, ultimately, to patient trials.1 The proposed approach depends on both sides' inputs: computational predictions and molecular designs from Isomorphic Labs, alongside MSD's curated datasets and development role.1 For patients, the relevant outcome is whether discovery-stage candidates eventually progress through testing, not simply whether the companies use AI in research.13
Overall, the agreement represents a strategic alignment of AI technology with established drug development pathways, aiming to address a high‑need cancer indication.1 Financial incentives tied to milestones and royalties are designed to align both parties’ interests throughout the discovery‑to‑market journey.1 The collaboration builds on Isomorphic Labs’ prior partnerships and recent financing, positioning the company to pursue its clinical‑trial ambitions despite a shifted timeline.234 Stakeholders will watch the partnership’s progress as an indicator of how AI can be operationalized within large‑scale pharmaceutical research.1 Isomorphic Labs will provide computational predictions and molecular designs, while MSD will lead development, manufacturing and commercialization.1 The financing rounds and the revised trial target describe different measures of progress: reported fundraising has grown from Series B to Series C, while the first-trial goal moved later.34
Structure
Who is connected to whom- 1Isomorphic Labs
- uses →Fact
- located in →Fact
- ← invests inFact
- enables →Fact
- produces →Fact
History
How it came to this- January 2024Earlier pharmaceutical partnershipsIsomorphic Labs announced partnerships with Eli Lilly and Novartis.
- May 2026Series B financing announcedThe company announced a $2.1 billion Series B.
- November 2026Series C financing announcedIsomorphic Labs announced a $5 billion Series C led by Greenoaks and Sequoia Capital.
- Nov. 19, 2026MSD collaboration announcedThe companies announced a research collaboration to seek small-molecule therapeutic candidates for an oncology indication.
- NowAnnounced Isomorphic Labs–MSD oncology drug-discovery collaboration announced
Impact
Spreading outward, level by level- Level 1Discovery work
Isomorphic Labs will provide in-silico predictions and molecular designs using its IsoDDE engine, while MSD will provide proprietary, curated datasets. The intended output is oncology candidates at the discovery stage, not clinical products.1
Fact - Level 2Development and product responsibilities
MSD will lead preclinical and clinical development, manufacturing, and commercialization for products arising from the collaboration.1
Fact - Level 3Isomorphic Labs’ potential compensation
The terms include an upfront payment, potential milestone payments and tiered net-sales royalties; Isomorphic Labs may choose to co-fund development for higher royalties.1
Fact - Level 4Potential progress toward patient testing
Any candidates would still need testing to establish safety and effectiveness in people, and clinical development carries substantial risk of failure. The collaboration’s success would therefore depend on candidates progressing beyond discovery.13
Fact
Sources
What each source supportsWritten by AI from the sources listed below: every fact was checked word for word against its source, and inference is marked apart. How we write